Peer-reviewed veterinary case report
Long-term exenatide drug release in cats from OKV-119 implant
By Klotsman, Michael et al.·Published in BMC veterinary research·2024·Okava Pharmaceuticals, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Drug release profile of a novel exenatide long-term drug delivery system (OKV-119) administered to cats.
- Species:
- cat
Plain-English summary
Five cats were implanted with a new drug delivery system called OKV-119, which releases a medication called exenatide to help with weight loss. After the implants were placed, the cats were monitored for over three months. During this time, four of the five cats ate less and lost at least 5% of their body weight, which they maintained throughout the study. This suggests that the OKV-119 implant can effectively help obese cats lose weight by delivering exenatide for an extended period.
People also search for: cat weight loss treatment · exenatide for cats · how to help my cat lose weight · cat obesity medication · long-term weight loss in cats
Abstract
Beneficial weight-loss properties of glucagon-like peptide-1 receptor agonists (GLP-1RA) in obese people, with corresponding improvements in cardiometabolic risk factors, are well established. OKV-119 is an investigational drug delivery system that is being developed for the long-term delivery of the GLP-1RA exenatide to feline patients. The purpose of this study was to evaluate the drug release characteristics of subcutaneous OKV-119 implants configured to release exenatide for 84 days. Following a 7-day acclimation period, five purpose-bred cats were implanted with OKV-119 protypes and observed for a 112-day study period. Food intake, weekly plasma exenatide concentrations and body weight were measured. Exenatide plasma concentrations were detected at the first measured timepoint (Day 7) and maintained above baseline for over 84 Days. Over the first 28 days, reduced caloric intake and a reduction in body weight were observed in four of five cats. In these cats, a body weight reduction of at least 5% was maintained throughout the 112-day study period. This study demonstrates that a single OKV-119 implant can deliver the GLP-1RA exenatide for a months long duration. Results suggest that exposure to exenatide plasma concentrations ranging from 1.5 ng/ml to 4 ng/ml are sufficient for inducing weight loss in cats.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/38762728/